Lymphoma Information

Romidepsin Active for Treatment of Refractory Cutaneous T-Cell Lymphoma (12/17/2008)
Researchers involved in an international multicenter trial have reported that romidepsin is effective for the treatment of patients with cutaneous T-cell lymphoma (CTCL). The results of this study were presented at the 50^th annual meeting of the American Society of Hematology in San Francisco on December 8, 2008.

Fostamatinib Disodium Effective for Diffuse B-Cell Lymphoma and CLL (12/17/2008)
Researcher involved in a U.S. multicenter trial have reported that the oral inhibitor of spleen tyrosine kinase (SYK), Fosamatinib disodium (FosD) (R788), has significant activity and is well tolerated in patients with diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). The results of this phase 1-2 study were reported in the Plenary Session of the 50^th annual meeting of the American Society of Hematology on December 7, 2008 in San Francisco.

Rituxan® and Intensive Chemotherapy Prolongs Remission of Mantle Cell Lymphoma (12/17/2008)
Researchers from the M. D. Anderson Cancer Center have reported that R (rituximab)-HyperCVAD alternated with R-MA (methotrexate/cytarabine) improves failure-free survival in patients with newly diagnosed mantle cell lymphoma. The details of this long-term follow-up report were presented at the 50^th Annual Meeting of the American Society of Hematology on December 9, 2008 in San Francisco.

Revlimid® Effective for Relapsed or Refractory Non-Hodgkin’s Lymphoma (12/16/2008)
Researchers involved in the international Phase II trial, NHL-003, have reported data that confirms the effectiveness of Revlimid® (linalidomide) for the treatment of patients with relapsed or refractory mantle-cell lymphoma and diffuse large B-cell lymphoma. These results were presented at the 50^th annual meeting of the American Society of Hematology on December 8, 2008 in San Francisco.

Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma (12/15/2008)
Researchers involved in the PROPEL (Pralatrexate in patients with Relapsed OR refractory PEripheral T-cell Lymphoma) trial have reported that 27% of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) experienced a complete or partial remission following treatment with the investigational drug pralatrexate. These results were presented at the 50^th Annual Meeting of the American Society of Hematology on December 8, 2008 in San Francisco.